Koselugo Selumetinib Application Scope

Koselugo (Selumetinib) is a MEK inhibitor used in the treatment of neurofibromatosis type 1 (NF1), a genetic disorder characterized by the development of multiple benign tumors called neurofibromas.

The drug is specifically approved for the treatment of pediatric patients aged 2 years and older with symptomatic inoperable plexiform neurofibromas.

Selumetinib works by targeting the MAPK pathway, a key signaling pathway that promotes tumor growth in NF1 patients. By inhibiting MEK, Koselugo helps to reduce the size and symptoms of neurofibromas, improving quality of life for affected individuals.

Koselugo Selumetinib Characteristics

Ingredients:
- Active ingredient: Selumetinib
- Excipients: Includes inactive ingredients used for the formulation of capsules.
Properties:Selumetinib is a selective MEK inhibitor. It works by blocking the activity of MEK1 and MEK2, which are enzymes involved in the MAPK/ERK signaling pathway that plays a significant role in the growth of tumors. By inhibiting these enzymes, Koselugo reduces tumor size and symptoms associated with neurofibromas in patients with neurofibromatosis type 1.
Specification:Available as 25 mg capsules.
Storage:Store at room temperature (between 20°C to 25°C), in a dry place, and protect from light.
Expiry Date:Typically 24 months from the manufacturing date (check packaging for exact expiry).
Executive Standard:Meets FDA or other relevant regulatory authority standards for oncology drugs.
Approval Number:Specific approval details from FDA or other regulatory bodies.
Manufacturer:AstraZeneca, the manufacturer of Koselugo.

Guidelines For The Use Of Koselugo Selumetinib

Dosage and Administration:

The recommended dose for pediatric patients aged 2 years and older is typically 25 mg orally twice daily.
The dose may be adjusted based on the patient’s response and tolerability.
Koselugo should be taken with or without food, but it should be swallowed whole and not chewed or crushed.

Adverse Reactions:

Common side effects include diarrhea, nausea, vomiting, skin rash, and fatigue.
Serious side effects may include liver toxicity, eye problems (such as retinal toxicity), and heart issues (such as QT prolongation).

Medication Limitations

Contraindications:Koselugo should not be used in patients with a known hypersensitivity to Selumetinib or any of its excipients.

Precautions:

Regular monitoring of liver function and heart health is recommended during treatment, especially in patients who have underlying cardiovascular conditions or are at risk for QT prolongation.
Caution should be exercised in patients who are on concomitant medications that may affect liver enzymes or cardiac function.

Koselugo Selumetinib Injection Interactions

Drug Interactions:

Koselugo may interact with other CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) or inducers (e.g., rifampin, carbamazepine), affecting Selumetinib metabolism.
It may also interact with drugs that prolong QT intervals, such as certain antiarrhythmics and antipsychotics.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine, China Medicine Wholesaler.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.